ACE-1831

N/A

Report date: 2026/02/14 20:00:22

Base Information

Drug NameACE-1831
Drug Alias NameAnti-CD20 Armed Allogeneic gamma delta T-cell TherapyACC-gamma delta T cell therapy ACE-1831ACC-γδ T cell therapy ACE-1831Antibody-Cell Conjugation (ACC) platform technology ACE-1831ACE-1831
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaImmunoglobulin G4-Related DiseaseLymphoma, Follicular +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanHong Kong +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAcepodia Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesAcepodia Biotech IncAcepodia Taiwan SubsidiarySyneos Health（Beijing）Inc Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaImmunoglobulin G4-Related DiseaseLymphoma, Follicular +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A